English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 36 Help

Selected(0)Clear Items/Page:    Sort:
FBP1 inhibits NSCLC stemness by promoting ubiquitination of Notch1 intracellular domain and accelerating degradation Journal article
He, Tianyu, Wang, Yanye, Lv, Wang, Wang, Yiqing, Li, Xinye, Zhang, Qingyi, Shen, Han Ming, Hu, Jian. FBP1 inhibits NSCLC stemness by promoting ubiquitination of Notch1 intracellular domain and accelerating degradation[J]. Cellular and Molecular Life Sciences, 2024, 81(1), 87.
Authors:  He, Tianyu;  Wang, Yanye;  Lv, Wang;  Wang, Yiqing;  Li, Xinye; et al.
Favorite | TC[WOS]:5 TC[Scopus]:5  IF:6.2/7.7 | Submit date：2024/05/16
Nsclc  Stemness  Fbp1  Nicd1  Ubiquitination  
Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis Journal article
Li, Yue Kang, Ge, Fu Jing, Liu, Xiang Ning, Zeng, Chen Ming, Qian, Mei Jia, Li, Yong Hao, Zheng, Ming Ming, Qu, Jing Jing, Fang, Liang Jie, Lu, Jin Jian, Yang, Bo, He, Qiao Jun, Zhou, Jian Ya, Zhu, Hong. Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis[J]. Acta Pharmacologica Sinica, 2024.
Authors:  Li, Yue Kang;  Ge, Fu Jing;  Liu, Xiang Ning;  Zeng, Chen Ming;  Qian, Mei Jia; et al.
Favorite | TC[WOS]:1 TC[Scopus]:1  IF:6.9/7.6 | Submit date：2024/12/26
Acquired Resistance  Cftr  Ivacaftor  Nsclc  Osimertinib  
Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents Journal article
Wu, Puhua, Zhang, Zhicheng, Zhou, Yan, Liu, Quan, Tam, Kin Yip, Su, Zhenhong. Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents[J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18, 4661-4679.
Authors:  Wu, Puhua;  Zhang, Zhicheng;  Zhou, Yan;  Liu, Quan;  Tam, Kin Yip; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:4.7/4.8 | Submit date：2024/11/05
Pdhk1  Dichloroacetophenone  Allosteric Pocket  Anti-nsclc Activity  Tumor Xenograft Mouse Model  
Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer Journal article
Zhang YiZhong, Lai HuanLing, Huang Chen, Jiang ZeBo, Yan HaoXin, Wang XuanRun, Xie Chun, Huang JuMin, Ren WenKang, Li JiaXin, Zhai ZhiRan, Yao XiaoJun, Wu QiBiao, Leung Elaine Lai Han. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer[J]. Phytomedicine, 2024, 128, 155431.
Authors:  Zhang YiZhong;  Lai HuanLing;  Huang Chen;  Jiang ZeBo;  Yan HaoXin; et al.
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:6.7/6.2 | Submit date：2024/05/16
Er Stress  Jnk  Nfat2  Nsclc  Pd-l1  Tanshinone Iia  
Preclinical evidence using synthetic compounds and natural products indicates that AMPK represents a potential pharmacological target for the therapy of pulmonary diseases Review article
2024
Authors:  Yang, Chao;  Rubin, Limor;  Yu, Xiyong;  Lazarovici, Philip;  Zheng, Wenhua
Favorite | TC[WOS]:4 TC[Scopus]:4  IF:10.9/12.9 | Submit date：2024/05/16
Ali  Ampk  Copd  Nsclc  Pf  
Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes Journal article
Wang, Kewei, Li, Zixi, Xuan, Ying, Zhao, Yong, Deng, Chao, Wang, Meidan, Xie, Chenjun, Yuan, Fenglai, Pang, Qingfeng, Mao, Wenjun, Cai, Dongyan, Zhong, Zhangfeng, Mei, Jie. Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes[J]. Cancer Cell International, 2023, 23(1), 229.
Authors:  Wang, Kewei;  Li, Zixi;  Xuan, Ying;  Zhao, Yong;  Deng, Chao; et al.
Favorite | TC[WOS]:3 TC[Scopus]:3  IF:5.3/5.0 | Submit date：2024/01/02
Biomarker  Immunotherapy  Nfe2l2  Ngs  Nsclc  
Combined inhibition of pyruvate dehydrogenase kinase 1 and hexokinase 2 induces apoptsis in non-small cell lung cancer cell models Journal article
Guo, Yizhen, Lu, Xianchen, Zhou, Yan, Chen, Wen Hua, Tam, Kin Yip. Combined inhibition of pyruvate dehydrogenase kinase 1 and hexokinase 2 induces apoptsis in non-small cell lung cancer cell models[J]. Experimental Cell Research, 2023, 433(2), 113830.
Authors:  Guo, Yizhen;  Lu, Xianchen;  Zhou, Yan;  Chen, Wen Hua;  Tam, Kin Yip
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:3.3/3.3 | Submit date：2024/01/02
Cancer Metabolism  Combination Therapy  Hk2  Nsclc  Pdk1  
Epigallocatechin gallate circumvents drug induced resistance in non-small cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis Journal article
Zhou, Yan, Huang, Shiqi, Guo, Yizhen, Ran, Maxoin, Shan, Wenying, Wen-Hau Chen, Tam, Kin Yip. Epigallocatechin gallate circumvents drug induced resistance in non-small cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis[J]. Phytotheraphy Research, 2023, 37(12), 5837-5853.
Authors:  Zhou, Yan;  Huang, Shiqi;  Guo, Yizhen;  Ran, Maxoin;  Shan, Wenying; et al.
Favorite | TC[WOS]:6 TC[Scopus]:8  IF:6.1/7.0 | Submit date：2023/08/22
Acquired Drug Resistance  Combination Therapy  Egcg  Egfr-tkis  Nsclc  Synergetic Effect  
CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer Journal article
Wang Jian, Li RunZe, Wang WenJun, Pan HuDan, Xie Chun, Yau LeeFong, Wang XingXia, Long WeiLi, Chen RuiHong, Liang TuLiang, Ma LinRui, Li JiaXin, Huang JuMin, Wu QiBiao, Liu Liang, He JianXing, Leung Elaine Lai Han. CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer[J]. Pharmacological Research, 2023, 194, 106850.
Authors:  Wang Jian;  Li RunZe;  Wang WenJun;  Pan HuDan;  Xie Chun; et al.
Favorite | TC[WOS]:7 TC[Scopus]:7  IF:9.1/9.0 | Submit date：2023/08/03
Cd8++++ Tim-3++++ t Cell  Cers4  Icis  Nsclc  Rhob  Sphingolipid Metabolism  
Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models Journal article
Guo, Yizhen, Zhou, Yan, Wu, Puhua, Ran, Maoxin, Xu, Ngai, Shan, Wenying, Sha, Ou, Tam, Kin Yip. Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models[J]. Chemico-Biological Interactions, 2023, 378, 110467.
Authors:  Guo, Yizhen;  Zhou, Yan;  Wu, Puhua;  Ran, Maoxin;  Xu, Ngai; et al.
Favorite | TC[WOS]:6 TC[Scopus]:6  IF:4.7/4.6 | Submit date：2023/07/19
Anticancer Effect  Dichloroacetophenone  Metabolic Alteration  Nsclc  Pdk